- Poster presentation
- Open Access
Metabolic monitoring of psychiatric patients on second-generation antipsychotics
© Markopoulou et al.; licensee BioMed Central Ltd. 2008
- Published: 17 April 2008
- Waist Circumference
- Abdominal Obesity
- Metabolic Abnormality
- Psychiatric Hospital
The current literature suggests that psychiatric patients have increased mortality and morbidity rates compared with the general population, primarily due to cardiovascular disease. There is increasing evidence that the use of second-generation antipsychotics is associated with an elevated risk in the appearance of metabolic abnormalities, which promote the risk of cardiovascular disease. Abdominal obesity seems to play a contributory role in the conferring risk for hyperglycemia and dyslipidaemia.
40 patients, all males, who are now hospitalized in the Psychiatric Hospital of Thessaloniki, were studied. Their mean age is 43 years old (25-78) and they are all on treatment for at least 1 year with second-generation antipsychotics. 33 are heavy smokers and only one exercise twice a week.
The mean waist circumference is 109.1 cm (ranging from 85 to 131 cm) and for 32 (80%) of them is above 102 cm. The mean BMI is 29.5 and in 36 (90%) cases is above 25 (BMI>25=overweight). 6 (15%) of them have high glucose level(>110mg/dl), 18 (30%) have high total cholesterol (>200mg/dl) and the mean blood pressure is estimated about 130/85 mmHg. 14 patients have triglycerides above normal (>150mg/dl) and 8 have low HDL levels (<40mg/dl). 8 patients need antihypertensive, 4 hypoglycemic and 2 hypolipidemic drugs. In sum, 14 patients (35%) need treatment for the metabolic disturbances, probably caused by the use of the SGAs.
Literature review and evidence from our study show the important role of weight-gain in psychiatric patients, as it is associated with a variety of adverse physiological effects, including changes in plasma glucose and lipid levels. Therefore, ongoing monitoring for patients who are being treated with SGAs and careful selection of treatment in high-risk patients is needed.
- North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004, 27: 596-601. 10.2337/diacare.27.2.596.Google Scholar
- Davis JM, Chen N: Old versus new: weighing the evidence between the first- and second-generation antipsychotics. Eur Psychiatry. 2005, 20: 7-14. 10.1016/j.eurpsy.2004.11.002.View ArticlePubMedGoogle Scholar
- Meyer JM: Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001, 21: 369-74. 10.1097/00004714-200108000-00003.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd.